

Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2008

Organocatalyzed Highly Enantioselective Michael Additions of Malonates to Enones Using Primary -Secondary Chiral Diamines

Ying-Quan Yang^a, Gang Zhao^{a,b}

^a Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, People's Republic of China;

^bLaboratory of Modern Synthetic Organic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, Shanghai 200032, People's Republic of China. **General Information**: Unless otherwise indicated, all compounds and reagents were purchased from commercial suppliers and used without further purification. Proton nuclear magnetic resonance spectra are recorded at 300 MHz. All chemical shifts (d) are given in ppm. NMR spectra were recorded on Varian EM-360A, Varian EM90 or Brucker AMX-300 NMR spectrometer. IR spectra were recorded on a Perkin-Elmer 983G instrument. MS or HRMS was recorded on a HP-5989A spectrometer. Melting points were determined on a METTLER-TOLEDO FP62 melting point apparatus and are uncorrected. Elemental analysis was performed on a Carlo-ERBA1106 instrument. HPLC analysis was carried out on WATERS equipment.

General procedure for the synthesis of catalysts 3a-i (**3g** was prepared according to known procedure^[1])



Typical Procedure for the Esterifation of Amino Acid

To a suspension of L-phenylalanine (10.0 g, 60.0 mmol) in ice-cooled dry methanol (120 mL) was added dropwise thionyl chloride (10.0 g, 85.0 mmol). After the solution was stirred at room temperature overnight, the solvent was removed under reduced pressure to give L-phenylalanine methyl ester hydrochloride as a colorless crystalline solid quantitatively, which was directly used in the next step without further purification.

Typical Procedure for the Preparation of Amino Amide^[2]

A solution of L-phenylalanine methyl ester hydrochloride (23.3 mmol) and propylamine (233.0 mmol) in anhydrous methanol (50 mL) was stirred at room

temperature for 3 days. The reaction mixture was concentrated, and the residue was purified by column chromatography on silica gel using petroleum ether / ethyl acetate (2:1) as eluant to give the (S)-2-amino-3-phenyl-N-propylpropanamide (3.9g).

Typical Procedure for the Reduction of Amino Amide to Diamine^[3]

To a solution of (*S*)-2-amino-3-phenyl-N-propylpropanamide (3.4 g, 16.3 mmol), in THF (60 mL) was added lithium aluminum hydride (3.7 g, 97.8 mmol) at 0?. After being stirred for 30 min at 0 °C, the reaction was allowed to heat at reflux for 48 h before the reaction was quenched with Na₂SO₄ and water with vigorous stirring at 0?. The white-gray suspension was filtered and the filtrate was concentrated. The crude product was purified by column chromatography on silica gel petroleum using petroleum ether / ethyl acetate (1:1) to give the desired product (*S*)-3-phenyl-N¹-propylpropane-1,2-diamine (**3d**) (2.69 g, 86% yield).

(S)-3-phenylpropane-1,2-diamine (3a)^[4]



Colorless oil; $[\alpha]_D{}^{27} = -16.2 (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl}_3) d 1.36 (brs, 4H), 2.45-2.57 (m, 2H), 2.74-2.82 (m, 2H), 2.91-2.99 (m, 1H), 7.18-7.33 (m, 5H) ppm.

(S)-N¹-methyl-3-phenylpropane -1,2 -diamine (3b)^[5]



Colorless oil; $[\alpha]_D^{25} = -2.0$ (c = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 1.51 (brs, 3H), 2.41-2.54 (m, 2H), 2.44 (s, 3H), 2.66 (dd, J = 4.9, 11.7 Hz, 1H), 2.79 (dd, J = 4.8, 13.5 Hz, 1H), 3.06-3.15 (m, 1H), 7.18-7.30 (m, 5H) ppm.

(S)-N¹-ethyl-3-phenylpropane -1,2 -diamine (3c)



Colorless oil; $[\alpha]_D^{27} = -1.9 (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl₃) d1.10 (t, J = 7.5 Hz, 3H), 1.28 (brs, 3H), 2.43-2.53 (m, 2H), 2.62-2.82 (m, 4H), 3.06-3.17 (m,

1H), 7.19-7.33 (m, 5H) ppm; ¹³C NMR (CDCl₃, 100 MHz) d 15.3, 42.9, 44.2, 52.5, 55.9, 126.1, 128.3, 129.2, 139.2 ppm; IR (neat): 3290, 2965, 2925, 1666, 1601, 1495, 1453, 1377, 1128, 745, 701 cm⁻¹; HRMS calc. $C_{11}H_{18}N_2$ (M⁺): 178.1470. Found: 178.1474.

(S)-3-phenyl-N¹-propylpropane -1,2-diamine (3d)



Colorless oil; $[\alpha]_D{}^{27} = 4.3 \ (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl}_3) d 0.92 (t, J = 6.9 Hz, 3H), 1.51-1.64 (m, 2H), 2.51-2.71 (m, 7H), 2.75-2.83 (m, 2H), 3.15-3.24 (m, 1H), 7.18-7.33 (m, 5H) ppm; ¹³C NMR (CDCl_3, 100 MHz) d 11.8, 22.5, 42.6, 51.6, 52.0, 55.1, 126.6, 128.7, 129.5, 138.7 ppm; IR (neat): 3273, 3026, 2929, 1661, 1602, 1495, 1454, 746, 701 cm⁻¹; HRMS calc. $C_{12}H_{20}N_2 \ (M^+)$: 192.1626. Found: 192.1623.

(S)-N¹-butyl-3-phenylpropane-1,2-diamine (3e)



Colorless oil; $[\alpha]_D^{27} = 3.1$ (*c* = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 0.91 (t, J = 7.5 Hz, 3H), 1.28-1.40 (m, 2H), 1.44-1.54 (m, 2H), 1.82 (brs, 3H), 2.45-2.55 (m, 2H), 2.58-2.68 (m, 2H), 2.71-2.82 (m, 2H), 3.09-3.18 (m, 1H), 7.19-7.33 (m, 5H) ppm; ¹³C NMR (CDCl₃, 100 MHz) d 14.2, 20.6, 32.0, 42.9, 49.8, 52.4, 55.9, 126.5, 128.7, 129.4, 139.1 ppm; IR (neat): 3285, 3026, 2927, 1665, 1602, 1495, 1454, 1377, 1129, 746, 701 cm¹; HRMS calc. C₁₃H₂₂N₂ (M⁺): 206.1783. Found: 206.1778.

(S)-4-methyl-N¹-propylpentane -1,2-diamine (3g)



Colorless oil; $[\alpha]_D^{27} = 12.5$ (*c* = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 0.88-0.95 (m, 9H), 1.19 (t, *J* = 6.9 Hz, 2H), 1.46-1.58 (m, 5H), 1.65-1.80 (m, 1H), 2.33 (dd, *J* = 8.4, 8.7 Hz, 1H), 2.54-2.65 (m, 3H), 2.84-2.93 (m, 1H) ppm; ¹³C NMR (CDCb, 100 MHz) d 11.5, 21.7, 23.0, 23.3, 24.4, 45.5, 48.5, 51.7, 56.9 ppm; IR (neat): 3301, 2956, 2929, 2872, 1465, 807 cm⁻¹; HRMS calc. C₉H₂₂N₂ (M⁺): 158.1783. Found:

158.1787.

(S)-2-phenyl-N¹-propylethane -1,2 -diamine (3h)



Colorless oil; $[\alpha]_D^{27} = 18.1$ (*c* = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 0.86 (t, J = 7.2 Hz, 3H), 1.41-1.48 (m, 2H), 1.67 (brs, 3H), 2.51-2.57 (m, 2H), 2.68-2.77 (m, 2H), 3.97-4.02 (m, 1H), 7.22-7.31 (m, 5H) ppm; ¹³C NMR (CDCl₅, 100 MHz) d 11.6, 23.0, 51.6, 55.4, 57.6, 126.3, 127.0, 128.3, 144.7 ppm; IR (neat): 3295, 2958, 2931, 2874, 1667, 1602. 1493, 1454, 1379, 760, 701 cm⁻¹; HRMS calc. C₁₁H₁₈N₂ (M⁺): 178.1470. Found: 178.1467.

(S)-3-(1H-indol-3-yl)-N¹-propylpropane-1,2-diamine (3i)



Yellow oil; $[\alpha]_D{}^{26} = -0.8 \ (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl₃) d 0.91 (t, J = 7.5 Hz, 3H), 1.45-1.54 (m, 5H), 2.48-2.62 (m, 3H), 2.63-2.71 (m, 1H), 2.79 (dd, J = 3.9, 11.7 Hz, 1H), 2.64 (dd, J = 4.5, 11.4 Hz, 1H), 3.20-3.28 (m, 1H), 7.03 (d, J = 1.8 Hz, 1H), 7.11 (t, J = 6.9 Hz, 1H), 7.20 (t, J = 7.2 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 8.42 (brs, 1H) ppm; ¹³C NMR (CDCl₃, 100 MHz) d 11.7, 22.7, 31.9, 51.1, 51.6, 55.5, 111.5, 111.6, 118.7, 119.0, 121.6, 123.4, 127.7, 136.6 ppm; IR (neat): 3244, 2928, 1619, 1456, 1340, 1104, 740, 702 cm⁻¹; HRMS calc. for C₁₄H₂₁N₃(M⁺): 231.1735. Found: 231.1728.

General procedure for the Michael reaction.

To a mixture of enone 2 (0.5 mmol), catalyst 3 (0.1 mmol) and TFA (0.1 mmol) in $CHCl_3(1.0 \text{ mL})$ was added malonate 1 (1.0 mmol) at ambient temperature. After 24 h of stirring, the reaction mixture was quenched with 1 M aqueous HCl solution and extracted with EtOAc. The combined organic layer was dried over Na₂SO₄, filtered, and concentrated to afford the corresponding Michael adduct 4 after flash column chromatography on silica gel(petroleum ether/Et₂O as eluent).

Dimethyl 2-(3-oxo-1-phenylbutyl)malonate (4aa)^[6]



White solid; $[\alpha]_D^{25} = -14.1$ (c = 1.0 in CHCl₃); m.p. 43-44 ? ; ¹H NMR (300 MHz, CDCl₃) d 2.03 (s, 3H), 2.87-3.02 (m, 2H), 3.50 (s, 3H), 3.72 (s, 3H), 3.73 (d, J = 9.6 Hz, 1H), 3.94-4.02 (m, 1H), 7.17-7.30 (m, 5H) ppm; enantiometric excess: 97%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 90:10, flow rate 1 mL/min; $t_{major} = 13.5$ min, $t_{minor} = 15.4$ min, ? = 254 nm).

Diethyl 2-(3-oxo-1-phenylbutyl)malonate (4ba)^[6]



White solid; $[\alpha]_D^{26} = -15.5$ (*c* = 1.0 in CHCl₃); m.p. 40-42 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.01 (t, *J* = 7.2 Hz, 3H), 1.26 (t, *J* = 7.2 Hz, 3H), 2.02 (s , 3H), 2.86-3.01 (m, 2H), 3.69 (d, *J* = 9.6 Hz, 1H), 3.91-4.01 (m, 3H), 4.19 (q, *J* = 7.2 Hz, 2H), 7.16-7.30 (m, 5H) ppm; enantiometric excess: 98%, determined by HPLC (Chiralpak AD column, hexane*i*/-PrOH 90:10, flow rate 1 mL/min, t_{major} = 12.5 min, t_{minor} = 18.6 min, ? = 254 nm).

Diisopropyl 2-(3-oxo-1-phenylbutyl)malonate (4ca)^[6]

Colorless oil; $[\alpha]_D{}^{26} = -19.4 (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl}_3) d 0.96 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 1.23 (dd, J = 1.5, 6.0 Hz, 6H), 2.00 (s, 3H), 2.84-2.99 (m, 2H), 3.64 (d, J = 10.2 Hz, 1H), 3.90-3.98 (m, 1H), 4.71-4.83 (m, 1H), 4.99-5.11(m, 1H), 7.15-7.30 (m, 5H) ppm; enantiomeric excess: >99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 90:10, flow rate 1

mL/min, $t_{maj or} = 9.6 \text{ min}$, $t_{minor} = 13.8 \text{ min}$, ? = 254 nm).

Diallyl 2-(3-oxo-1-phenylbutyl)malonate (4da)^[6]



Colorless oil; $[\alpha]_D{}^{26} = -12.1 (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl}_3) d 2.02 (s, 3H), 2.87-3.02 (m, 2H), 3.78 (d, J = 9.6 Hz, 1H), 3.96-4.04 (m, 1H), 4.38 (d, J = 5.7 Hz 2H), 4.63 (d, J = 5.4 Hz, 2H), 5.10-5.15 (m, 2H), 5.22-5.34 (m, 2H), 5.57-5.70(m, 1H), 5.81-5.94 (m, 1H), 7.17-7.30 (m, 5H) ppm; enantiomeric excess: 98%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 90:10, flow rate 1 mL/min, t_{major}=13.6 min, t_{minor} = 20.3 min, ? = 254 nm).

Dibenzyl 2-(3-oxo-1-phenylbutyl)malonate (4ea)^[6]



White solid; $[\alpha]_D^{26} = -7.1$ (*c* = 1.0 in CHCl₃); m.p. 85-88 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.95 (s, 3H), 2.88 (d, *J* = 6.9 Hz, 2H), 3.82 (d, *J* = 9.6 Hz, 1H), 3.96-4.04 (m, 1H), 4.89 (s, 2H), 5.13 (s, 2H), 7.04-7.07 (m, 2H), 7.18-7.38 (m, 13H) ppm; enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 90:10, flow rate 1 mL/min, t_{major} =33.0 min, t_{minor} = 46.0 min, ? = 254 nm).

Dibenzyl 2-(1-(naphthalen-2-yl)-3-oxobutyl)malonate (4eb)^[6]

 $CH(CO_2Bn)_2$



White solid; $[\alpha]_D^{25} = -7.6$ (c = 1.0 in CHCl₃); m.p. 66-68 ?; ¹H NMR (300 MHz, CDCl₃) d 1.94 (s, 3H), 2.89-3.04 (m, 2H), 3.94 (d, J = 9.6 Hz, 1H), 4.14-4.22 (m, 1H), 4.84 (s, 2H), 5.15 (s, 2H), 6.90 (d, J = 7.5 Hz, 2H), 7.01 (t, J = 6.9 Hz, 2H), 7.18 (t, J

= 7.2 Hz, 1H), 7.25-7.36 (m, 6H), 7.43-7.47 (m, 2H), 7.64 (m, 1H), 7.72-7.78 (m, 3H) ppm; enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, $t_{major} = 35.6 \text{ min}$, $t_{minor} = 47.8 \text{ min}$, ? = 254 nm).

Dibenzyl 2-(1-(4-fluorophenyl)-3-oxobutyl)malonate (4ec)



White solid; $[\alpha]_D^{25} = -8.5$ (c = 1.0 in CHCl₃); m.p. 105-107 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.95 (s, 3H), 2.84 (d, J = 6.3 Hz, 2H), 3.77 (d, J = 9.6 Hz, 1H), 3.94-4.01 (m, 1H), 4.91 (s, 2H), 5.14 (s, 2H), 6.87 (t, J = 9.6 Hz, 2H), 7.08-7.16 (m, 4H), 7.26-7.35 (m, 8H) ppm; ¹³C NMR (CDCl₃, 100MHz) d 30.5, 39.9, 47.3, 57.5, 67.4, 67.6, 115.5, 115.7, 128.5, 128.6, 128.7, 128.9, 130.0, 135.2, 135.4, 136.2, 167.5, 168.0, 205.9 ppm; IR (neat): 3068, 1745, 1714, 1603, 1512, 1256, 1153, 757, 700 cm⁻¹; MS (70 ev): m/z (%): 357 (0.68) [M⁺-Bn], 91 (100); Anal. calcd. for C₂₇H₂₅FO₅: C: 72.31; H: 5.62. Found: C: 72.28; H: 5.63. enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =27.1 min, t_{minor} = 43.4 min, ? = 254 nm).

Dibenzyl 2-(1-(4-chlorophenyl)-3-oxobutyl)malonate (4ed)^[6]



White solid; $[\alpha]_D^{25} = -8.7$ (*c* = 1.0 in CHCl₃); m.p. 82-84 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.95 (s, 3H), 2.84 (d, *J* = 6.9 Hz, 2H), 3.77 (d, *J* = 9.6 Hz, 1H), 3.91-4.00 (m, 1H), 4.92 (s, 2H), 5.14 (s, 2H), 7.07-7.09 (m, 2H), 7.11-7.16 (m, 4H), 7.26-7.35 (m, 8H) ppm; enantiomeric excess: >99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =27.6 min, t_{minor} = 44.3 min, ? = 254 nm).

Dibenzyl 2-(1-(3-chlorophenyl)-3-oxobutyl)malonate (4ee)



White solid; $[\alpha]_D^{25} = -8.3$ (c = 1.0 in CHCl₃); m.p. 66-68 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.97 (s, 3H), 2.86 (d, J = 7.2 Hz, 2H), 3.79 (d, J = 9.9 Hz, 1H), 3.94-4.01 (m, 1H), 4.92 (s, 2H), 5.13 (s, 2H), 7.07-7.34 (m, 14H) ppm; ¹³C NMR (CDCl₃, 100MHz) d 30.2, 39.9, 46.7, 56.9, 67.2, 67.4, 126.5, 127.5, 128.2, 128.3, 128.5, 128.6, 129.7, 134.2, 134.8, 135.0, 142.5, 167.1, 167.6, 205.3 ppm; IR (neat): 3064, 1731, 1597, 1570, 1455, 1259, 1156, 746, 696 cm⁻¹; MS (70 ev): m/z (%): 373 (1.06) [M⁺-Bn], 91 (100); Anal. calcd. for C₂₇H₂₅ClO₅: C: 69.75; H: 5.42. Found: C: 69.70; H: 5.36. enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, $t_{major} = 21.3$ min, $t_{minor} = 24.9$ min, ? = 254 nm).

Dibenzyl 2-(1-(2-chlorophenyl)-3-oxobutyl)malonate (4ef)



Colorless oil; $[\alpha]_D^{25} = -0.2$ (c = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 1.99 (s, 3H), 2.92-3.10 (m, 2H), 4.10 (d, J = 9.0 Hz, 1H), 4.43-4.50 (m, 1H), 4.99 (s, 2H), 5.10 (d, J = 1.5 Hz, 2H), 7.09-7.32 (m, 14H) ppm; ¹³C NMR (CDCl₃, 100MHz) d 30.2, 37.3, 45.3, 55.1, 67.4, 67.5, 127.2, 128.4, 128.5, 128.6, 128.7, 128.8, 130.4, 134.2, 135.3, 135.4, 137.8, 167.7, 168.1, 206.1 ppm; IR (neat): 3033, 1730, 1498, 1476, 1455, 1375, 1216, 751, 697 cm⁻¹; MS (70 ev): m/z (%): 429 (0.68) [M⁺-Cl], 91 (100); Anal. calcd. for C₂₇H₂₅ClO₅: C: 69.75; H: 5.42. Found: C: 69.84; H: 5.52. enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =22.0min, t_{minor} = 28.0 min, ? = 254 nm).

Dibenzyl 2-(1-(4-bromophenyl)-3-oxobutyl)malonate (4eg)



White solid; $[\alpha]_D^{24} = -6.9 (c = 1.0 \text{ in CHCl}_3)$; m.p. 77-80 ? ; ¹H NMR (300 MHz, CDCl}_3) d 1.95 (s, 3H), 2.83 (d, J = 6.9 Hz, 2H), 3.77 (d, J = 9.6 Hz, 1H), 3.91-3.99 (m, 1H), 4.92 (s, 2H), 5.14 (s, 2H), 7.03-7.07 (m, 4H), 7.26-7.35 (m, 10H) ppm; ¹³C NMR (CDCb, 100MHz) d 30.5, 40.0, 47.1, 57.2, 67.5, 67.6, 121.4, 128.6, 128.8,128.9, 130.2, 131.9, 135.1, 135.3, 139.6, 167.5, 167.9, 205.7 ppm; IR (neat): 3034, 1735, 1491, 1456, 1408, 1261, 1133, 755, 699 cm⁻¹; MS (70 ev): m/z (%): 417 (0.42) [M⁺-Bn], 91 (100); Anal. calcd. for C₂₇H₂₅BrO₅: C: 63.66; H: 4.95. Found: C: 63.72; H: 5.05. enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, $t_{major} = 30.0$ min, $t_{minor} = 49.0$ min, ? = 254 nm).

Dibenzyl 2-(3-oxo-1-p-tolylbutyl)malonate (4eh)



White solid; $[\alpha]_{D}^{25} = -8.1$ (*c* = 1.0 in CHCl₃); m.p. 86-89 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.94 (s, 3H), 2.28 (s, 3H), 2.85 (d, *J* = 6.9 Hz, 2H), 3.79 (d, *J* = 9.9 Hz, 1H), 3.92-4.00 (m, 1H), 4.90 (s, 2H), 5.13 (s, 2H), 7.00-7.09 (m, 6H), 7.25-7.33 (m, 8H) ppm; ¹³C NMR (CDCl₅, 100MHz) d 21.3, 30.5, 40.4, 47.4, 57.7, 67.3, 67.5, 128.2, 128.4, 128.5, 128.7, 128.8, 129.5, 135.4, 135.5, 137.0, 137.4, 167.7, 168.2, 206.3 ppm; IR (neat): 3033, 1739, 1709, 1514, 1496, 1297, 1222, 732, 698 cm⁻¹; MS (70 ev): *m/z* (%): 444 (0.42) [M⁺], 91 (100); Anal. calcd. for C₂₈H₂₈O₅: C: 75.65; H: 6.35. Found: C: 75.82; H: 6.37. enantiomeric excess: >99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =23.8min, t_{minor} = 36.5 min, ? = 254 nm).

Dibenzyl 2-(1-(4-methoxyphenyl)-3-oxobutyl)malonate (4ei)



White solid; $[\alpha]_D^{25} = -10.2$ (*c* = 1.0 in CHCl₃); m.p. 54-56 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.94 (s, 3H), 2.83 (d, *J* = 6.9 Hz, 2H), 3.75-3.79 (m, 4H), 3.91-4.00 (m, 1H), 4.90 (s, 2H), 5.14 (s, 2H), 6.74 (d, *J* = 8.7 Hz, 2H), 7.07-7.12 (m, 4H), 7.26-7.32 (m, 8H) ppm; ¹³C NMR (CDCl₃, 100MHz) d 30.2, 39.8, 47.2, 55.1, 57.5, 67.0, 67.2, 113.9, 128.1, 128.2, 128.4, 128.5, 129.1, 132.0, 135.0, 135.2, 158.6, 167.4, 167.9, 206.0 ppm; IR (neat): 3066, 2953, 1745, 1715, 1611, 1517, 1456, 1249, 1139, 696 cm⁻¹; MS (70 ev): *m/z* (%): 460 (0.78) [M⁺], 91 (100); Anal. calcd. for C₂₈H₂₈O₆: C:73.03; H: 6.13. Found: C: 73.28; H: 6.19. enantiomeric excess: >99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =35.5min, t_{minor} = 60.9 min, ? = 254 nm).

Dibenzyl 2-(1-(4-nitrophenyl)-3-oxobutyl)malonate (4e j)^[6]



Yellow solid; $[\alpha]_D^{25} = -9.0$ (*c* = 1.0 in CHCl₃); m.p. 67-69 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.96 (s, 3H), 2.88-2.91 (m, 2H), 3.82 (d, *J* = 9.3 Hz, 1H), 4.03-4.11 (m, 1H), 4.93 (s, 2H), 5.15 (s, 2H), 7.07 (d, *J* = 6.3 Hz, 4H), 7.23-7.35 (m, 10H), 7.96 (d, *J* = 8.7 Hz, 2H) ppm; enantiomeric excess: 99%, determined by HPLC (Chiralpak OD-H column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} =43.4min, t_{minor} =39.2 min, ? = 254 nm).

Dibenzyl 2-(1-(furan-2-yl)-3-oxobutyl)malonate (4ek)^[6]



Colorless oil; $[\alpha]_D{}^{25} = -3.5 (c = 1.0 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl₃) d 2.02 (s, 3H), 2.80-3.00 (m, 2H), 3.90 (d, J = 7.8 Hz, 1H), 4.10-4.17 (m, 1H), 5.04 (s, 2H), 5.12 (s, 2H), 6.02 (d, J = 3.3 Hz, 1H), 6.19 (dd, J = 1.5, 3.0 Hz, 1H), 7.21-7.33 (m,

11H) ppm; enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, $t_{major} = 21.5$ min, $t_{minor} = 25.2$ min, ? = 254 nm).

Dibenzyl 2-(3-oxo-1-phenylpentyl)malonate (4el)^[6]

White solid; $[\alpha]_D^{25} = -0.9$ (c = 1.0 in CHCl₃); m.p. 69-71 ?; ¹H NMR (300 MHz, CDCl₃) d 0.88 (t, J = 7.2 Hz, 3H), 2.08-2.32 (m, 2H), 2.78-2.93 (m, 2H), 3.84 (d, J = 9.9 Hz, 2H), 3.98-4.06 (m, 1H), 4.88 (s, 2H), 5.13 (d, J = 1.5 Hz), 7.04-7.32 (m, 14H) ppm; enantiomeric excess: 99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, $t_{major} = 24.4$ min, $t_{minor} = 40.6$ min, ? = 254 nm).

Dibenzyl 2-(3-oxo-1,3-diphenylpropyl)malonate (4em)^[7]



White solid; $[\alpha]_D^{25} = -14.7$ (*c* = 1.0 in CHCl₃); m.p. 87-89 ? ; ¹H NMR (300 MHz, CDCl₃) d 3.44 (d, *J* = 6.6 Hz, 2H), 3.95 (d, *J* = 9.6 Hz, 1H), 4.18-4.26 (m, 1H), 4.91 (s, 2H), 5.14 (d, *J* = 4.5 Hz), 7.05-7.08 (m, 2H), 7.18-7.28 (m, 13H), 7.36-7.41 (m, 2H), 7.48-7.54 (m, 1H), 7.81 (d, *J* = 7.8 Hz, 2H) ppm; enantiomeric excess: >99%, determined by HPLC (Chiralpak AD column, hexane/*i*-PrOH 80:20, flow rate 0.75 mL/min, t_{major} = 43.4min, t_{minor} = 89.3min, ? = 254 nm).

Dibenzyl 2-(2-oxooctan-4-yl)malonate (4en)^[6]



Colorless oil; $[\alpha]_D^{27} = -5.1$ (c = 1.0 in CHCl₃); ¹H NMR (300 MHz, CDCl₃) d 0.80-0.84 (m, 3H), 1.20-1.33 (m, 6H), 2.03 (s, 3H), 2.41-2.50 (m, 1H), 2.63-2.69 (m, 2H), 3.66 (d, J = 5.4 Hz, 1H), 5.12-5.14 (m, 4H), 7.26-7.31 (m, 10H) ppm;

enantiomeric excess: 98%, determined by HPLC (Chiralpak OD-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, t_{major} 10.0 min, $t_{minor} = 9.3$ min, ? = 254 nm).

Dibenzyl 2-(3-oxocyclohexyl)malonate (4eo)^[6]



White solid; $[\alpha]_D^{25} = -14.7 (c = 1.0 \text{ in CHCl}_3)$; m.p. 62-64 ? ; ¹H NMR (300 MHz, CDCl₃) d 1.39-1.53 (m, 1H), 1.57-1.71 (m, 1H), 1.88-1.92 (m, 1H), 1.98-2.06 (m, 1H), 2.14-2.28 (m, 2H), 2.35-2.50 (m, 2H), 2.51-5.61 (m, 1H), 3.41 (d, J = 7.8 Hz, 1H), 5.15 (d, J = 1.8 Hz, 4H), 7.26-7.34 (m, 10H) ppm; enantiomeric excess: 90%, determined by HPLC (Chiralpak AS-H column, hexane/*i*-PrOH 95:5, flow rate 1.0 mL/min, t_{major} 56.4 min, t_{minor} = 47.5 min, ? = 254 nm).

Reference

- [1] [1] J. Christoffers, A. Mann, Chem. Eur. J. 2001, 7, 1014.
- [2] D. Zhang, X. Xing, G. D. Cuny, J. Org. Chem. 2006, 71, 1750.
- [3] H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger, H. Schönenberger, *Eur. J. Med. Chem.* 1990, 25, 35.
- [4] D. A. Alonso, P. G. Andersson, J. Org. Chem. 1998, 63, 9455.
- [5] N. Halland, R. G. Hazell, K. A. Jørgensen, J. Org. Chem. 2002, 67, 8331.
- [6] N. Halland, P. S. Aburel, K. A. Jørgensen, Angew. Chem. 2003, 115, 685;
 Angew. Chem., Int. Ed. 2003, 42, 661.
- [7] T. Ooi, D. Ohara, K. Fukumoto, K. Maruoka, Org. Lett. 2005, 7, 3195.

NMR spectra for catalysts 3a-i



3b (¹H NMR)



 $3c(^{1}HNMR)$



3c (¹³C NMR)



3d (¹H NMR)



3d (¹³C NMR)



3e (¹H NMR)







3e (¹³C NMR)





3g (¹³C NMR)



3h (¹H NMR) ERRY REGENERATION 1 NH2 N Y4-30-A 4/59 2.97 200 2 PPM T 8 4 3 7

3h (¹³C NMR)



 $3i(^{1}HNMR)$





NMR spectra for compounds 4

4aa (1 H NMR)





4ca(¹H NMR)





 $4ea(^{1}H NMR)$



4eb (¹H NMR)



4ec (1 H NMR)





4ec (13 C NMR)



4ed (1 H NMR)





4ee (1 H NMR)



4ee (13 C NMR)





 $4ef(^{1}H NMR)$



 $4eg(^{1}HNMR)$

PPM



 $4eg\,(^{13}\!C\,NMR)$



4eh (¹H NMR)



4eh (¹³C NMR)



 $4ei(^{1}HNMR)$



 $4ei(^{13}C NMR)$



 $4ej(^{1}HNMR)$





4ek (¹H NMR)



 $4el(^{1}HNMR)$



4em (¹H NMR)

7,018 7,75147 7,75147 7,75147 7,75147 7,75147 7,751477777777777777777777	5.149 5.149 4.259 4.237 4.237 4.237 3.430 3.430 3.430 3.430 3.430 3.430
	an anna



4en (¹H NMR)



4eo (1 H NMR)



HPLC spectra for compounds 4









HPLC spectra for compound 4ba







Chromatogram (Y3-79-D iPr.org) 45 CH(CO₂i-Pr)₂ 40 35 30 9.668 25 电压(mv) 13.822 20 15 10 5 0 -5 -10 12 Time(min) 9 10 15 11 13 14 Results Peak ID Ret Time Height Peak No. Area Conc. 9.668 20252.668 379815.688 50.5905 1 13.822 13903.822 370949.344 49.4095 2 Total 34156.490 750765.031 100.0000









HPLC spectra for compound 4ea



38





HPLC spectra for compound 4eb





HPLC spectra for compound 4ec







Peak No.	Peak ID	Ret Time	Height	Area	Cone.	
1		27.088	52287.852	2813233.250	99.3208	_
2		43.400	309.684	19237.299	0.6792	
Total			52597.535	2832470.549	100.0000	- 0

HPLC spectra for compound 4ed





HPLC spectra for compound 4ee





HPLC spectra for compound 4ef



43



HPLC spectra for compound 4eg



HPLC spectra for compound 4eh



Results						
Peak No.	Peak ID	Ret Time	Height	Area	Conc.	
1		23.838	36614.727	2021049.125	99.7360	
2		36.475	566.317	5349.400	0.2640	
Total			37181.043	2026398.525	100.0000	

HPLC spectra for compound 4ei





HPLC spectra for compound 4ej



Results						
Peak No.	Peak ID	Ret Time	Height	Area	Conc.	
1		38.033	74661.117	9948830.000	50.0652	
2		47.007	39918.914	9922903.000	49.9348	
Total			114580.031	19871733.000	100.0000	





 Image: Constraint of the second sec

HPLC spectra for compound 4ek



HPLC spectra for compound 4el



Results						
Peak No.	Peak ID	Ret Time	Height	Area	Conc.	
1		24.740	49303.113	2416972.750	48.4954	
2		41.162	29237.162	2566946.500	51.5046	
Total			78540.275	4983919.250	100.0000	



Chromatogram (Y4-64-J.org)

HPLC spectra for compound 4em



Results						
Peak No.	Peak ID	Ret Time	Height	Area	Conc.	
1		42.373	54598.988	4673873.500	49.6945	
2		85.573	25924.840	4731344.500	50.3055	
Total			80523.828	9405218.000	100.0000	



HPLC spectra for compound 4en

Total

71574.582

6317887.851

100.0000



HPLC spectra for compound 4eo



Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		47,510	1112.948	76518.453	4.9893
2		56.443	11140.774	1457132.250	95.0107
Total			12253.722	1533650.703	100.0000